These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 24810715

  • 1. Chemical strategies for development of ATR inhibitors.
    Llona-Minguez S, Höglund A, Jacques SA, Koolmeister T, Helleday T.
    Expert Rev Mol Med; 2014 May 09; 16():e10. PubMed ID: 24810715
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Molecular Pathways: Targeting ATR in Cancer Therapy.
    Karnitz LM, Zou L.
    Clin Cancer Res; 2015 Nov 01; 21(21):4780-5. PubMed ID: 26362996
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Targeting the S and G2 checkpoint to treat cancer.
    Chen T, Stephens PA, Middleton FK, Curtin NJ.
    Drug Discov Today; 2012 Mar 01; 17(5-6):194-202. PubMed ID: 22192883
    [Abstract] [Full Text] [Related]

  • 7. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
    Charrier JD, Durrant SJ, Golec JM, Kay DP, Knegtel RM, MacCormick S, Mortimore M, O'Donnell ME, Pinder JL, Reaper PM, Rutherford AP, Wang PS, Young SC, Pollard JR.
    J Med Chem; 2011 Apr 14; 54(7):2320-30. PubMed ID: 21413798
    [Abstract] [Full Text] [Related]

  • 8. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.
    Foote KM, Nissink JWM, McGuire T, Turner P, Guichard S, Yates JWT, Lau A, Blades K, Heathcote D, Odedra R, Wilkinson G, Wilson Z, Wood CM, Jewsbury PJ.
    J Med Chem; 2018 Nov 21; 61(22):9889-9907. PubMed ID: 30346772
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.
    Teng PN, Bateman NW, Darcy KM, Hamilton CA, Maxwell GL, Bakkenist CJ, Conrads TP.
    Gynecol Oncol; 2015 Mar 21; 136(3):554-61. PubMed ID: 25560806
    [Abstract] [Full Text] [Related]

  • 11. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z, Oleinick NL, Zhang J.
    Radiother Oncol; 2018 Mar 21; 126(3):450-464. PubMed ID: 29054375
    [Abstract] [Full Text] [Related]

  • 12. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.
    Gorecki L, Andrs M, Rezacova M, Korabecny J.
    Pharmacol Ther; 2020 Jun 21; 210():107518. PubMed ID: 32109490
    [Abstract] [Full Text] [Related]

  • 13. Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR).
    Ramachandran SA, Jadhavar PS, Singh MP, Sharma A, Bagle GN, Quinn KP, Wong PY, Protter AA, Rai R, Pham SM, Lindquist JN.
    Bioorg Med Chem Lett; 2017 Feb 15; 27(4):750-754. PubMed ID: 28131712
    [Abstract] [Full Text] [Related]

  • 14. Sulfoximines as ATR inhibitors: Analogs of VE-821.
    Hendriks CMM, Hartkamp J, Wiezorek S, Steinkamp AD, Rossetti G, Lüscher B, Bolm C.
    Bioorg Med Chem Lett; 2017 Jun 15; 27(12):2659-2662. PubMed ID: 28479198
    [Abstract] [Full Text] [Related]

  • 15. Targeted cancer therapies based on the inhibition of DNA strand break repair.
    O'Connor MJ, Martin NM, Smith GC.
    Oncogene; 2007 Dec 10; 26(56):7816-24. PubMed ID: 18066095
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Inhibition of the ATR kinase enhances 5-FU sensitivity independently of nonhomologous end-joining and homologous recombination repair pathways.
    Ito SS, Nakagawa Y, Matsubayashi M, Sakaguchi YM, Kobashigawa S, Matsui TK, Nanaura H, Nakanishi M, Kitayoshi F, Kikuchi S, Kajihara A, Tamaki S, Sugie K, Kashino G, Takahashi A, Hasegawa M, Mori E, Kirita T.
    J Biol Chem; 2020 Sep 11; 295(37):12946-12961. PubMed ID: 32675286
    [Abstract] [Full Text] [Related]

  • 19. ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response.
    Blackford AN, Jackson SP.
    Mol Cell; 2017 Jun 15; 66(6):801-817. PubMed ID: 28622525
    [Abstract] [Full Text] [Related]

  • 20. DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy.
    Ashwell S, Zabludoff S.
    Clin Cancer Res; 2008 Jul 01; 14(13):4032-7. PubMed ID: 18593978
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.